A Phase II Trial of Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Patients With Unresectable or Metastatic Melanoma
Phase of Trial: Phase II
Latest Information Update: 01 Dec 2017
At a glance
- Drugs Dabrafenib (Primary) ; Pembrolizumab (Primary) ; Trametinib (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 27 Nov 2017 Status changed from not yet recruiting to recruiting.
- 25 Sep 2017 Planned initiation date changed from 30 Jun 2017 to 30 Sep 2017.
- 16 May 2017 New trial record